Representatives from the Foundation and from Genzyme, a medical biotech company with a focus on rare diseases, have agreed on April 17, 2014 in Montreal to collaborate on the ARSACS research project. Genzyme is a subsidiary of the French multinational pharmaceutical company Sanofi.

(l to r) Dr Peter McPherson, Dr Kalle Gehring, Dr Bernard Brais, Jean Groleau, Dr Lamya Shihaubuddin (Genzyme), Sonia Gobeil, Dr Anne McKinney, Dr Richard Gregory (Genzyme).

(l to r) Sonia Gobeil, Dr Lamya Shihaubuddin, Dr Richard Gregory and Jean Groleau.

The Foundation is working also in collaboration with Genome Canada and the Canadian Institutes of Health Research Canada by providing financial support to research projects to develop treatments for ARSACS .